Our Mission

Biobide’s aim is to accelerate R&D process for Pharma, Biotech, Chemical, Cosmetic and Nutraceutical companies minimizing risks through our zebrafish services, adding value to clients R&D&i mainly in preclinical area.

We are a CRO specialized in zebrafish working under Good Laboratory Practice (GLP) and thanks to our automated and innovative tools, we have developed and validated time and cost effective Toxicity and Efficacy Assays, as well as disease models to be used in preclinical stages.

The followed strategy is based on:

Excellent services:

to develop, in an environment of Good Laboratory Practice, reliable and relevant assays for our Customers, Regulatory Bodies and, ultimately, for Human Health based on an experimental design and interpretation of results supported by a first-rate technology platform and innovative tools.

Expert team:

to integrate into our processes the capabilities required to understand and apply advances in genetic and physiological research, automation, image analysis and all other areas of knowledge which impact on our business model.

Global business:

having a network of alliances and strategic partnerships to develop and launch together new solutions to the market.


to achieve our Customers and Regulatory bodies being the promoters of our services.

Our History

Biobide was founded in 2005 in order to resolve the main problem that contemporary biotechnological and pharmaceutical companies were facing: how to deal with the low success rate in marketing new drugs and block busters. In 2014, the company was acquired by the Bionaturis Group. During 2018, Bionaturis acquired ADL Biopharma by a reverse acquisition.

The Newco after the integration, Biatgroup is a biotech European leader focused in R&D and manufacturing high value fermentation products for human and animal health. Biatgroup is quoted on the alternative Spanish stock exchange for SME (MaB, ticker BST).

Board of Directors

Victor Infante

Mr. Infante holds PhD in Science and Chemical degree. Appointed CEO and President of Bionaturis since 2005 and Managing Director of BNT Pacific Limited, and Chairman of Biobide Board of Directors.

Andoni Cruz Pacheco
Co-founder and General Manager

Besides Biobide, Mr. Cruz is also co-founder of several ongoing companies, such as Imatec Innovación, GTCluster and Cyberclick. Mr. Cruz is Member of the Board of Biobide.

Arantza Muriana Miralles
Co-founder and R+D Management Director

Mrs. Muriana has the bachelor of Pharmacy and Master degree in R+D+i of New Drugs at the University of Navarra. In addition, she has a MBA from the San Pablo CEU University of Madrid and she is Member of the Board of Biobide.

Scientific Advisors

Dr. Calum Macrae
Scientific Advisor

Dra. Robyn Leigh Tanguay
Scientific Advisor

Scientific Team

Andrea Weiner
Study Director

Dr. Weiner has a bachelor’s degree in Biotechnology and a MSc. in Biotechnology Business. She has over 18 years of experience working with zebrafish. She became a Study Director in Biobide in 2021 being in charge of neurotoxicity and developmental toxicity studies.

Ana del Pozo
Study Director

Dr. del Pozo has over 12 years of experience working with zebrafish in different fields. As postdoctoral researcher, she studied zebrafish developmental neurobiology at both, Tel Aviv University (Sagol School of Neuroscience) and Uppsala University.

Oihane Jaka
Study Director

Oihane completed her PhD in Neuroscience in the laboratory of Dr. Adolfo López de Munain at the Biodonostia Health Institute, one of the state's leading groups in the field of muscular diseases.

Beatriz Molina
Study Director

Dr. Molina is preclinical Study Director of the CNS group at Biobide - Spain. She was certified in 2015 from the Eberhard Karls University Tübingen with a master's in Molecular Medicine, specialized in diseases related to the nervous system.